This seminar is hosted by the Physiology & Pharmacology Department.

Target Audience

Des Moines University faculty, staff, and students.

Purpose

On December 1, 2018, medicinal cannabis will be available at five dispensaries located across the state of Iowa. This includes oils, creams and capsules that can be taken by Iowa residents who suffer from one of the eight qualifying medical conditions for medicinal cannabis treatment, such as cancer or untreatable pain. Join us on Friday, November 30 to discuss medical research and state-level reports related to cannabis medicinal uses and outcomes. Your patients will ask questions… do you have the answers?

Speakers

Lucas Nelson, JD
General Manager, MedPharm Iowa, LLC

Lucas received his bachelors of business administration and accounting from James Madison University. In 2014, he received his law degree from Indiana University Maurer School of Law. In April 2017, He joined Kemin Industries and currently serves as the general manager of MedPharm Iowa. 

Rebecca Lucas
Business Development Manager, Kemin Industries

Rebecca has worked for Kemin Industries for over 10 years. Various roles in global business intelligence researcher and technical business development associate. Rebecca’s current role is global business development manager. Prior to her time at Kemin Industeries, Rebecca was a research assistant with USDA. She received her bachelor’s degree in microbiology from Iowa State University and is currently enrolled in the University of Iowa Tippie College of Business.

Karry Smith, PhD, MPH
Founder and Medical Writer, Periphas Science Group

Dr. Karry Smith earned her Master of Public Health degree in Epidemiology and her PhD in Cell and Developmental Biology from the University of Iowa. Following two postdoctoral fellowships at the University of Iowa Carver College of Medicine (Biochemistry) and the Mayo Clinic (Physiology and Biomedical Engineering), Dr. Smith  joined a contract research organization as a medical writer and consultant. In this position, she authors regulatory documents for pharmaceutical and device companies that support the approval of new therapies by the FDA. Dr. Smith has extensive experience teaching a wide range of science topics from biochemistry to genetics. She has given numerous talks about gene therapy/editing and precision medicine and has an interest in these and other health sciences topics as they relate to drug development and the future of medicine.